Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 96 (RPL23AP96) is a pseudogene, meaning it is a non-functional, non-protein-coding copy of the gene encoding ribosomal protein L23a. Pseudogenes such as RPL23AP96 are DNA segments that closely resemble functional genes but have lost their ability to code for functional proteins over evolutionary time due to mutations or genetic drift. This family of pseudogenes is numerous within the human genome, related to the functional RPL23A gene which encodes a component of the 60S large ribosomal subunit. To date, there is no information describing RPL23AP96 as having any biological function, therapeutic relevance, or clinical significance. It is neither considered a protein-coding gene nor a therapeutic target, and there are no known clinical or pharmacological implications associated with this locus. RPL23AP96 is not a drug target, does not code for a protein, and does not have aliases, biological function, disease role, or clinical utility in biomarker, safety, or drug-interaction contexts. It is one of many related pseudogenes derived from the RPL23A ribosomal protein gene.
None (not a target for drug action)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 96 (RPL23AP96).